Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use. [PDF]
Blumenberg V +18 more
europepmc +1 more source
Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma. [PDF]
Brooks C +8 more
europepmc +1 more source
Immune checkpoint inhibitors-related cytokine storm syndrome: a systematic review of characteristics, treatment, and outcomes. [PDF]
Jin Q, Fu Q, Fei B.
europepmc +1 more source
Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System. [PDF]
Elsallab M +8 more
europepmc +1 more source
Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma. [PDF]
Wang AX +23 more
europepmc +1 more source
CRS and ICANS: Early detection and personalized management. [PDF]
Kim J.
europepmc +1 more source
Endotheliopathy in CAR T-Cell Therapy: Mechanistic Insights into the VWF/ADAMTS13 Axis and the Angiopoietin-Tie2 Pathway. [PDF]
de Bruijn S +3 more
europepmc +1 more source
Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors. [PDF]
Lim JU +17 more
europepmc +1 more source
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation. [PDF]
Li T +13 more
europepmc +1 more source

